Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

However, the pharmacist did not have access to the participants’ clinical notes or medication records and all clinical decision-making, including prescribing, remained with the GPResults from 17 Randomized Controlled Trials using Frailty PhenotypeIntervention, population, referenceFrailty assessmentFrailty-specific resultsInterpretationPharmacological intervention: antiplatelet medications Intervention: prasugrel vs clopidogrel Population: 9326 adults aged 65 years or older with unstable angina Follow-up: 3 months Reference: White, 2016, 52 countries42 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (0)B: frailty phenotype (1 to 2)C: frailty phenotype (3 to 5)Cardiovascular death, myocardial infarction, or StrokeA: HR 0.90 (0.77, 1.06)B: HR 1.34 (1.04, 1.73)C: HR 0.89 (0.54, 1.46)Prasugrel was associated with higher rates of composite of cardiovascular death, myocardial infarction, or stroke compared with clopidogrel in patients with 1 to 2 components of the frailty phenotype (p-for-interaction = 0.032)Pharmacological intervention: anticoagulants Intervention: very-low-dose edoxaban vs placebo Population: 984 patients with atrial fibrillation aged 80 years or older Follow-up: 4 months Reference: Akashi, 2022, Japan43 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (0 to < 3)B: frailty phenotype (3 to 5)Stroke or systemic embolismA: HR 0.24 (0.10, 0.59)B: HR 0.35 (0.14, 0.87)All-cause deathA: HR 1.46 (0.85, 2.51)B: HR 0.72 (0.45, 1.18)Net clinical composite outcomeA: HR 0.99 (0.65, 1.51)B: HR 0.77 (0.50, 1.17)There was no evidence that the effect of edoxaban compared with placebo on stroke or systemic embolism (p-for-interaction = 0.55), all-cause death (p-for-interaction = 0.06), and net clinical composite outcome was different across the frailty spectrum (p-for-interaction = 0.42)Pharmacological intervention: osteoporosis medications Intervention: strontium ranelate vs placebo Population: 5082 older women with osteoporotic Follow-up: 3 years Reference: Rolland, 2010, 12 countries16 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (0)B: frailty phenotype (1 to 2)C: frailty phenotype (3 to 5)Vertebral fractureA: HR 0.70 (0.57, 0.86)B: HR 0.55 (0.46, 0.67)C: HR 0.42 (0.24, 0.74)There was no evidence that the effect of strontium ranelate compared with placebo on vertebral fracture was different across the frailty spectrum (p-for-interaction = 0.11)Pharmacological intervention: androgen medications Intervention: testosterone gel vs placebo Population: 262 men aged 65 years or older Follow-up: 6 months Reference: Srinivas-Shankar, 2010, UK15 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (1)B: frailty phenotype (2)C: frailty phenotype (3)D: frailty phenotype (4)IME-PTAdjusted difference: 9.48 (− 4.05, 23.02)There was no evidence that testosterone gel compared with placebo on IME-PT was different across the frailty spectrum (p-for-interaction = 0.68)Non-pharmacological intervention: physical activity and exercise Intervention: individual training (Nintendo Wii Fit Plus) vs physical activity education Population: 30 older adults aged 71 to 92 years Follow-up: 30 days Reference: Gomes, 2018, Brazil14 Fried frailty criteria (range, 0 to 5)A: frailty phenotype, 1 to 2B: frailty phenotype, ≥ 3Mini-BESTest score at final and follow-up assessments†(Final)A: mean 17.6 (14.8, 20.5) vs mean 19.1 (17.4, 20.9)B: mean 19.6 (16.6, 22.6) vs mean 15.8 (13.6, 18.0)(Follow-up)A: mean 16.9 (14.1, 19.7) vs mean 19.0 (17.2, 20.8)B: mean 17.6 (14.3, 20.9) vs mean 15.7 (13.0, 18.3)FGA at final and follow-up assessments†(Final)A: mean 19.5 (17.2, 21.9) vs mean 18.2 (16.2, 20.3)B: mean 18.0 (16.2, 19.8) vs mean 15.8 (13.5, 18.0)(Follow-up)A: mean 19.9 (17.4, 22.4) vs mean 19.8 (17.8, 21.7)B: mean 19.0 (17.1, 20.9) vs mean 17.6 (15.4, 19.9)There was no evidence that the effect of individual training (Nintendo Wii Fit Plus) compared with physical activity education on Mini-BESTest score (p-for-interaction > 0.05), and FGA (p-for-interaction > 0.05) was different across the frailty spectrum Intervention: LSRT vs HSRT vs control Population: 60 adults aged 60 years and older Follow-up: NR Reference: Coelho-junior, 2021, Brazil45 Fried frailty criteria (range, 0 to 5)A: Frailty phenotype (1 to 2)B: Frailty phenotype (3 to 5)Refer to Appendix TableThere was no evidence that the effect of LSRT and HSRT compared with control on physical performance was different across the frailty spectrum (p-for-interaction = NR) Interaction: functional walking vs usual pattern of activities Population: 278 adults aged 63 to 98 years Follow-up: 52 weeks Reference: Faber, 2006, Netherland46 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (0)B: frailty phenotype (1 to 2)C: frailty phenotype (3 to 5)POMAB: mean 1.1 (0.4, 1.8)C: mean 0.5 (− 0.6, 1.7)PPSB: mean 0.7 (0.3, 1.2)C: mean − 0.7 (− 1.3, − 0.0)Time to first fallB: HR 0.62 (0.29, 1.33)C: HR 2.95 (1.64, 5.32)There was no evidence that the effect of functional walking compared with usual pattern of activities on PPS was different across the frailty spectrum (p-for-interaction = NR)Functional walking was associated with higher risks of fall compared with usual pattern of activities in patients with 3 or more frailty phenotypes, but not in patients with 1 to 2 components of the frailty phenotype (p-for-interaction = 0.002) Intervention: tailored, progressive physical rehabilitation vs usual care Population: 349 adults aged 60 years or older with heart failure Follow-up: 3 months Reference: Kitzman, 2021,US47 Modified Fried frailty criteria (range, 0 to 5)A: frailty phenotype (0)B: frailty phenotype (1 to 2)C: frailty phenotype (3 to 5)SPPB score(between-group difference in mean score, 95% CI)A or B: 0.7 (− 0.1, 1.5)C: 2.1 (1.3, 2.8)There was no evidence that the effect of tailored, progressive physical rehabilitation compared with usual care on SPPB score was different across the frailty spectrum (p-for-interaction = NR) Intervention: physical rehabilitation intervention vs attention control Population: 337 patients 60 years and older hospitalized for acute decompensated heart failure Follow-up: 3 months Reference: Pandey, 2023, US37 Modified Fried frailty criteria (range, 0 to 5)A: frailty phenotype (1 to 2)B: frailty phenotype (3 to 5)SPPB scoreA: effect size 0.8 (− 0.1, 1.6)B: effect size 2.1 (1.3, 2.9)Physical rehabilitation intervention was associated with greater improvement in SPPB score compared with attention control in patients with 3 or more frailty phenotypes, but not in patients with 1 to 2 components of the frailty phenotype (p-for-interaction = 0.03) Intervention: physical exercise vs usual care Population: 299 adults aged 65 years and older Follow-up: 24 months Reference: Suikkanen, 2020, Finland49 Modified Fried frailty criteria (range, 0 to 5)A: frailty phenotype (1 to 2)B: frailty phenotype (3 to 5)Days at homeA: IRR 1.03 (0.96, 1.11)B: IRR 1.04 (0.96, 1.12)There was no evidence that the effect of physical exercise compared with usual care on days at home was different across the frailty spectrum (p-for-interaction = NR) Intervention: resistance-type exercise training vs no exercise training Population: 127 adults aged 65 years or older with pre-frail or frail Follow-up: 24 weeks Reference: Tieland, 2015, Netherland50 Fried frailty criteria (range, 0 to 5)A: Frailty phenotype (1 to 2)B: Frailty phenotype (3 to 5)Dominant handgrip strengthNRThere was no evidence that the effect of resistance-type exercise training compared with no exercise training on dominant handgrip strength was different across the frailty spectrum (p-for-interaction > 0.05) Intervention: moderate-intensity physical activity vs health education Population: 1635 adults aged 70 to 89 years with functional limitations Follow-up: 2 years Reference: Trombetti, 2018, US51 Study of Osteoporotic Fractures Index (range, 0 to 3)A: frailty phenotype (0 to < 2)B: frailty phenotype (2 to 3)MMD‡A vs B: HR 0.92 vs HR 0.96PBD‡A vs B: HR 0.92 vs HR 0.94There was no evidence that the effect of moderate-intensive physical activity compared with health education on MMD (p-for-interaction = 0.91) and PBD (p-for-interaction = 0.64) was different across the frailty spectrum Intervention: walking and nutrition vs walking vs control Population: 227 adults aged 65 years and older Follow-up: 6 months Reference: Yamada, 2015, Japan52 Modified Cardiovascular Health Study criteria (range, 0 to 5)A: frailty phenotype (0 to 2)B: frailty phenotype (3 to 5)SMIA: 1.02% vs 1.11% vs − 0.86%B: 3.16% vs 0.64% vs − 3.87%IGF-1A: 21.4% vs 22.5% vs 8.6%B: 31.8% vs 14.5% vs 9.4%DHEA-SA: 26.6% vs 18.1% vs 8.4%B: 15.9% vs 19.7% vs − 0.8%25(OH)DA: 39.9% vs 32.0% vs 6.1%B: 45.2% vs 33.6% vs − 5.6%There was no evidence that the effect of walking and nutrition or walking compared with control on SMI, IGF-1, DHEA-S, and 25(OH)D was different across the frailty spectrum (p-for-interaction = NR)Non-pharmacological intervention: diabetes management Intervention: multimodal interventiona vs usual care Population: 964 adults aged over 70 years older adults with type 2 diabetes mellitus and functional impairment Follow-up: 12 months Reference: Rodriguez-Manas, 2019, 7 European countries44 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (1 to 2)B: frailty phenotype (3 to 5)Changes in physical function: NRThere was no evidence that the effect of multimodal intervention compared with usual care on physical function was different across the frailty spectrum (p-for-interaction = 0.49)Multicomponent intervention Intervention: ①MIb + n3 PUFAc vs placebo②n3 PUFA vs Placebo③MI + placebo vs placebo Population: 1680 adults aged 70 years and older without dementia but with subjective memory complaints Follow-up: 3 years Reference: Tabue-teguo, 2018, France20 Fried frailty criteria (range, 0 to 5)A: frailty phenotype (0)B or C: frailty phenotype (1 to 5)3-year TMTADifference of score change①Pre-frail, − 4.029Non-frail, 1.134②Pre-frail, 0.246Non-frail, 3.478③Pre-frail, 2.268Non-frail, 2.9513-year TMTBDifference of score change①Pre-frail, − 4.093Non-frail, − 1.466②Pre-frail, − 6.313Non-frail, 1.798③Pre-frail, 12.891Non-frail, − 4.297Refer to Appendix Table for more outcomesThere was no evidence that the effect of MI and n3 PUFA program compared with placebo on cognitive function was different across the frailty spectrum (p-for-interaction > 0.05) Intervention: multifactorial, interdisciplinary interventiond vs usual care Population: 241 adults aged 70 years and older without severe cognitive impairment Follow-up: 1 year Reference: Fairhall, 2012, Australia53 Fairhall, 2014, Australia54 Modified CHS frailty criteria (range 0 to 5)A: frailty phenotype (3)B: frailty phenotype (4 to 5)Life Space Assessment scoree(3 months)A: 9.0 (5.3, 12.7)B: 2.0 (− 2.8, 6.8)(12 months)NRGait speed(3 months)NR(12 months)A: 0.01 m/s (− 0.05, 0.07)B: 0.13 m/s (0.04, 0.22)SPPB: NRPPA: NRMultifactorial, interdisciplinary intervention was associated with greater life space compared with usual care in patients with 3 components of the frailty phenotype at 3 months (p-for-interaction = 0.03), but no longer effective at 12 months (p-for-interaction = 0.4)Multifactorial, interdisciplinary intervention was associated with greater gait speed compared with usual care in patients with 4 to 5 components of the frailty phenotype at 12 months (p-for-interaction = 0.03), but not effective at 3 months (p-for-interaction = 0.9)There was no evidence that multifactorial, interdisciplinary intervention compared with usual care on SPPB and PPA was different across frailty spectrum (p-for-interaction = NR)Abbreviations: HR, hazard ratio; NR, not reported; IME-PT, isometric knee extension peak torque; MMD, major mobility disability; PBD, persistent mobility disability; POMA, performance-oriented mobility assessment; PPS, physical performance score; SPPB, Short Physical Performance Battery; LSRT, low-speed resistance training; HSRT, high-speed resistance training; FGA, functional gait assessment; SMI, skeletal muscle mass index; IGF-1, insulin-like growth factor; DHEA-S, dehydroepiandrosterone sulfate; 25 (OH)D, 25-hydroxy vitamin D; MI, multidomain intervention; n3 PUFA, omega-3 polyunsaturated fatty acids; CHS, Cardiovascular Health Study; PPA, Physiological Profile Assessmentp-for-interaction: an indicator used to infer whether the effect of an intervention on outcome measures is significant at different levels of frailty*Data were extracted from supplemental files†Data were extracted by GetData Graph Digitizer software‡Calculations are based on published data in the literatureaA multimodal intervention composed of (i) an individualized and progressive resistance exercise program for 16 weeks; (ii) a structured diabetes and nutritional educational program over seven sessions; and (iii) investigator-linked training to ensure optimal diabetes carebThe multidomain intervention (MI) consisted of 2-h group sessions focusing on three domains (cognitive stimulation, physical activity, and nutrition) and a preventive consultation (at baseline, 12 months, and 24 months) and for omega-3 polyunsaturated fatty acids supplementation, participants took two capsules of either placebo or polyunsaturated fatty acids dailycThe n-3 PUFA supplementation group consumed a daily dose of DHA (800 mg) and EPA (a maximum amount of 225 mg) for 3 yearsdIntervention was coordinated by two physiotherapists with extensive relevant experience and delivered by an interdisciplinary team comprising the physiotherapists, a dietician, a geriatrician, a rehabilitation physician and a nurse.

Source: Study Selection and Characteristics of the Included Trials. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis not reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review

Source: Article title.

We did not perform meta-analysis due to heterogeneity of frailty tools and intervention types.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review

Systematic review · Journal of General Internal Medicine · 2024

Original publication title

Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review

Aaron Yao; Linhui Gao; Jiajun Zhang; Joyce M. Cheng; Dae Hyun Kim

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: What background does the paper provide?

The effect of clinical interventions may vary by patients’ frailty status. Understanding treatment effect heterogeneity by frailty could lead to frailty-guided treatment strategies and reduce overtreatment and undertreatment. This systematic review aimed to examine the effect modification by frailty in randomized controlled trials (RCTs) that evaluate pharmacological, non-pharmacological, and multicomponent interventions.

Source: Background

Abstract: What methods does the paper describe?

We searched PubMed, Web of Science, EMBASE, and ClinicalTrial.gov, from their inception to 8 December 2023. Two reviewers independently extracted trial data and examined the study quality with senior authors.

Source: Methods

Abstract: Discussion

The efficacy of clinical interventions often varied by frailty levels, suggesting that frailty is an important factor to consider in recommending clinical interventions in older adults.

Source: Discussion

Abstract: Registration

PROSPERO registration number CRD42021283051.

Source: Registration

Abstract: Results

Sixty-one RCTs that evaluated the interaction between frailty and treatment effects in older adults were included. Frailty was evaluated using different tools such as the deficit accumulation frailty index, frailty phenotype, and other methods. The effect of several pharmacological interventions (e.g., edoxaban, sacubitril/valsartan, prasugrel, and chemotherapy) varied according to the degree of frailty, whereas other treatments (e.g., antihypertensives, vaccinations, osteoporosis medications, and androgen medications) demonstrated consistent benefits across different frailty levels. Some non-pharmacological interventions had greater benefits in patients with higher (e.g., chair yoga, functional walking, physical rehabilitation, and higher dose exercise program) or lower (e.g., intensive lifestyle intervention, psychosocial intervention) levels of frailty, while others (e.g., resistance-type exercise training, moderate-intensive physical activity, walking and nutrition or walking) produced similar intervention effects.

Specific combined interventions (e.g., hospital-based disease management programs) demonstrated inconsistent effects across different frailty levels.

Source: Results
Authors’ abstract

Background

The effect of clinical interventions may vary by patients’ frailty status. Understanding treatment effect heterogeneity by frailty could lead to frailty-guided treatment strategies and reduce overtreatment and undertreatment. This systematic review aimed to examine the effect modification by frailty in randomized controlled trials (RCTs) that evaluate pharmacological, non-pharmacological, and multicomponent interventions.

Methods

We searched PubMed, Web of Science, EMBASE, and ClinicalTrial.gov, from their inception to 8 December 2023. Two reviewers independently extracted trial data and examined the study quality with senior authors.

Results

Sixty-one RCTs that evaluated the interaction between frailty and treatment effects in older adults were included. Frailty was evaluated using different tools such as the deficit accumulation frailty index, frailty phenotype, and other methods. The effect of several pharmacological interventions (e.g., edoxaban, sacubitril/valsartan, prasugrel, and chemotherapy) varied according to the degree of frailty, whereas other treatments (e.g., antihypertensives, vaccinations, osteoporosis medications, and androgen medications) demonstrated consistent benefits across different frailty levels. Some non-pharmacological interventions had greater benefits in patients with higher (e.g., chair yoga, functional walking, physical rehabilitation, and higher dose exercise program) or lower (e.g., intensive lifestyle intervention, psychosocial intervention) levels of frailty, while others (e.g., resistance-type exercise training, moderate-intensive physical activity, walking and nutrition or walking) produced similar intervention effects.

Specific combined interventions (e.g., hospital-based disease management programs) demonstrated inconsistent effects across different frailty levels.

Discussion

The efficacy of clinical interventions often varied by frailty levels, suggesting that frailty is an important factor to consider in recommending clinical interventions in older adults.

Registration

PROSPERO registration number CRD42021283051.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11606-024-08732-8.

Publication and source details

Original title: Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review

Aaron Yao; Linhui Gao; Jiajun Zhang; Joyce M. Cheng; Dae Hyun Kim

Journal of General Internal Medicine · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.National Institute of HealthR01AG071809K24AG073527Kim Dae Hyun

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:20:30.688385+00:00

DOI: 10.1007/s11606-024-08732-8 · PMC11169165